Bimekizumab Achieves Dual Clearance of Nail and Skin Psoriasis
Key Takeaways
Bimekizumab outperformed adalimumab, ustekinumab, and secukinumab in achieving dual clearance of skin and nail psoriasis.
Clearance rates were maintained or improved over 3–4 years of continuous or switched treatment.
Findings highlight bimekizumab’s sustained efficacy in treating difficult-to-clear nail psoriasis.
In pooled analyses of phase III and IIIb trials, bimekizumab was associated with significantly higher rates of complete clearance of both skin and nail psoriasis compared to adalimumab, ustekinumab, and secukinumab in patients with moderate-to-severe plaque psoriasis.
The analysis included patients from the BE SURE, BE VIVID, and BE RADIANT trials and their respective open-label extensions. All patients had baseline nail involvement, defined as a modified Nail Psoriasis Severity Index (mNAPSI) >0, and continued into long-term extension studies. Complete clearance was defined as achieving both PASI 100 (100% improvement from baseline in Psoriasis Area and Severity Index) and mNAPSI 0.
During the controlled trial periods, bimekizumab-treated patients consistently demonstrated higher rates of complete skin and nail clearance:
In BE SURE (week 24), 45.8% of patients on bimekizumab achieved dual clearance versus 18.3% of those on adalimumab.
In BE VIVID (week 52), the rates were 51.1% for bimekizumab versus 26.5% for ustekinumab.
In BE RADIANT (week 48), bimekizumab reached 63.3% dual clearance versus 36.1% with secukinumab.
Long-term outcomes remained favorable for bimekizumab. At year 4 in BE SURE/BE BRIGHT, 57.7% of patients who switched from adalimumab and 49.1% of continuous bimekizumab users achieved complete skin and nail clearance. Comparable patterns were observed in BE VIVID/BE BRIGHT and BE RADIANT, with switchers and continuous users showing maintained or improved clearance rates over time.
“Numerically higher proportions of bimekizumab-treated patients achieved concurrent complete skin and nail clearance versus adalimumab, ustekinumab, and secukinumab,” the authors wrote. “Clearance rates increased following switch to bimekizumab, and were sustained long-term in both switchers to bimekizumab and continuous bimekizumab-treated patients.”